rs117042478 (POLR3B): AMD and VLDL Lipoproteins

Key takeaways

• A large UK Biobank study (72,376 participants) found that very small VLDL depletion in blood appears likely causal for age-related macular degeneration
• 84 blood metabolic markers showed significant association with AMD, with lipoprotein subclasses making up 39% of associated metabolites
• 19 metabolites showed likely causal roles in AMD through Mendelian randomization analysis
• Age is the most prominent risk factor for AMD, with metabolites contributing a much smaller share of predictive value
• The provided study does not explicitly name rs117042478 in its text, so evidence directly attributing these findings to this variant is preliminary

What the research says

A study of 72,376 UK Biobank donors (1,353 with AMD, 71,023 controls) identified 84 blood metabolic markers significantly associated with age-related macular degeneration (AMD, the leading cause of irreversible vision loss in adults over 50 in developed countries) after adjusting for age and sex (false discovery rate-adjusted P < 0.05). Genome-wide association analyses were performed for 325 metabolites in 98,316 European UK Biobank participants, and 2-sample Mendelian randomization (a statistical method that uses genetic variants as causal instruments to infer whether a factor drives an outcome, rather than merely correlating with it) identified 19 metabolites with likely causal roles in AMD. Six of these involved very small very low-density lipoprotein (VLDL, a class of fat-carrying particles in the blood) subclasses and phospholipid-to-total-lipid ratios in medium VLDL, leading the authors to postulate that depletion of circulating very small VLDLs is likely causal for AMD.

Reported associations

• Age-related macular degeneration (AMD): In UK Biobank (N=72,376; AMD n=1,353), 84 out of 325 metabolic markers showed significant association with AMD (FDR-adjusted P < 0.05), with lipoprotein subclasses comprising 39% of associated metabolites
• Very small VLDL lipoprotein levels: Depletion of circulating very small VLDL subclasses identified as likely causal for AMD through 2-sample Mendelian randomization in UK Biobank (N=98,316 for the GWAS component); this finding was among 19 metabolites showing likely causal effects
• Phospholipid-to-total-lipid ratio in medium VLDL: Among the 19 metabolites with likely causal roles in AMD development identified through Mendelian randomization

Evidence quality

The sole provided study used a large UK Biobank cohort (N=72,376 for metabolite-AMD association analyses; N=98,316 for the metabolite GWAS component) with a 3-tiered methodological design that included association analysis, GWAS, and 2-sample Mendelian randomization for causal inference. Multiple-testing correction used false discovery rate adjustment (FDR-adjusted P < 0.05), and the models accounted for age and sex as confounders. The study authors note that age was the primary predictive factor in the risk model, with metabolites contributing a much smaller incremental value. Critically, rs117042478 and POLR3B are not explicitly named in the provided study text, meaning direct evidence linking this specific variant to the reported AMD and VLDL associations cannot be confirmed from the available source material. Evidence linking this variant to these findings should be considered preliminary pending direct variant-level reporting.

Lifestyle considerations

No lifestyle considerations on file for this variant.